Sulindac
Sulindac is a prodrug NSAID metabolized in vivo to an active form that induces apoptosis by inhibiting cGMP phosphodiesterase. It is used in cancer research, particularly in studies of colorectal and prostate cancer, for investigating apoptotic pathways in both cellular and animal models.
Product Specifications
CAS Number
38194-50-2
Product Name Alternative
Epithelial-mesenchymal transition (EMT), FDA, MK 231, MK231, MK-231, migration, immunomodulatory agent, Autophagy, Arthrocine, Clinoril, colorectal cancer (CRC), COX, Sulindac, Sulindac sulfoxide, pMMR, SIRT1
Field of Research
Cell Biology, Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.09% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.61 mM) ; Ethanol:9 mg/mL (25.25 mM) ; DMSO:250 mg/mL (701.44 mM)
Smiles
C (=C/1\C=2C (C (CC (O) =O) =C1C) =CC (F) =CC2) \C3=CC=C (S (C) =O) C=C3
Molecular Formula
C20H17FO3S
Molecular Weight
356.41
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
RPC30417-01 20 µg
Recombinant Human Hyaluronan and proteoglycan link protein 1 (HAPLN1)
Sign In for Pricing
View Details 
RPC30417-02 100 µg
Recombinant Human Hyaluronan and proteoglycan link protein 1 (HAPLN1)
Sign In for Pricing
View Details 
RPC30417-03 1 mg
Recombinant Human Hyaluronan and proteoglycan link protein 1 (HAPLN1)
Sign In for Pricing
View Details 